Moderna (MRNA) Receivables - Net (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables - Net data on file, last reported at $203.0 million in Q1 2026.

• On a quarterly basis, Receivables - Net fell 18.47% year-over-year to $203.0 million in Q1 2026; TTM through Mar 2026 was $203.0 million, a 18.47% decrease from a year earlier, with the FY2025 full-year figure at $368.0 million, down 47.28% from the prior year.
• Receivables - Net for Q1 2026 stood at $203.0 million, down from $368.0 million in the prior quarter.
• Over the last five years, Receivables - Net for MRNA reached as high as $3.2 billion in Q1 2022 and fell as low as $61.0 million in Q2 2025.
• Historically, Receivables - Net has averaged $1.3 billion across 5 years, with a median of $1.1 billion in 2023.
• Across the five-year window, Receivables - Net plunged 91.38% in 2023 and jumped 46.41% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $1.4 billion in 2022, then rose by 14.37% to $1.6 billion in 2023, then slumped by 55.93% to $698.0 million in 2024, then tumbled by 47.28% to $368.0 million in 2025, then sank by 44.84% to $203.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $203.0 million in Q1 2026, $368.0 million in Q4 2025, and $2.0 billion in Q3 2025.